2019 ESC/EAS Guidelines for the management of dyslipidaemias (with 2025 Focused Update)
The 2019 ESC/EAS guideline set the "lower is better" LDL-cholesterol targets and risk-based intensity of lipid lowering; the 2025 Focused Update reinforced early combination therapy and the role of newer agents. The register's landmark statin, non-statin and residual-risk trials are grouped by mechanism below.
This guideline cites 9 of the 199 landmark trials in our Cardiology register.
Statins — intensity & outcomes3
- 2008JUPITERCardiology · Lipids · StatinsJustification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
- 2004PROVE-ITCardiology · Lipids · StatinsPravastatin or Atorvastatin Evaluation and Infection Therapy — Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22)
- 19944SCardiology · Lipids · StatinsScandinavian Simvastatin Survival Study
Non-statin LDL lowering (ezetimibe, PCSK9, bempedoic acid)4
- 2023CLEAR OutcomesCardiology · Lipids · Non-statin LDLBempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
- 2018ODYSSEY OUTCOMESCardiology · Lipids · PCSK9 inhibitorEvaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
- 2017FOURIERCardiology · Lipids · PCSK9iFurther Cardiovascular Outcomes Research with PCSK9 Inhibition
- 2015IMPROVE-ITCardiology · Lipids · Non-statin LDLImproved Reduction of Outcomes: Vytorin Efficacy International Trial